SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-086031
Filing Date
2024-04-03
Accepted
2024-04-03 16:32:00
Documents
15
Period of Report
2024-04-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d819383d8k.htm   iXBRL 8-K 24424
2 EX-99.1 d819383dex991.htm EX-99.1 34291
6 GRAPHIC g819383g0404005146257.jpg GRAPHIC 4035
  Complete submission text file 0001193125-24-086031.txt   195639

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20240402.xsd EX-101.SCH 2889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20240402_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20240402_pre.xml EX-101.PRE 11287
18 EXTRACTED XBRL INSTANCE DOCUMENT d819383d8k_htm.xml XML 3652
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 24819296
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)